LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 259 filers reported holding LIGAND PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 3.43 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,616,000 | -50.1% | 15,500 | -35.1% | 0.03% | -87.8% |
| Q4 2018 | $3,239,000 | +4.7% | 23,870 | +111.8% | 0.21% | +8.7% |
| Q3 2018 | $3,094,000 | +23.7% | 11,270 | -6.6% | 0.20% | -8.0% |
| Q2 2018 | $2,501,000 | -9.1% | 12,070 | -27.5% | 0.21% | -21.7% |
| Q1 2018 | $2,750,000 | -20.9% | 16,650 | -34.4% | 0.27% | -25.1% |
| Q4 2017 | $3,478,000 | -47.5% | 25,400 | -47.8% | 0.36% | -47.7% |
| Q3 2017 | $6,631,000 | -13.8% | 48,700 | -23.2% | 0.69% | -23.7% |
| Q2 2017 | $7,697,000 | -38.6% | 63,400 | -46.5% | 0.91% | -45.6% |
| Q1 2017 | $12,546,000 | -0.8% | 118,540 | -4.8% | 1.67% | -35.5% |
| Q4 2016 | $12,653,000 | +16.0% | 124,530 | +16.5% | 2.59% | +31.5% |
| Q3 2016 | $10,908,000 | +28.8% | 106,880 | +50.5% | 1.97% | +23.7% |
| Q2 2016 | $8,472,000 | -3.3% | 71,030 | -13.2% | 1.59% | +0.3% |
| Q1 2016 | $8,763,000 | – | 81,830 | – | 1.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knott David M Jr | 115,000 | $7,682 | 2.90% |
| VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
| Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
| Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
| RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
| Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
| Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
| WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
| Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
| ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |